Benjamin Machinas Beneski - Mar 1, 2025 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
SVP, Chief Technical Officer
Signature
/s/Earl Douglas, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
Mar 1, 2025
Transactions value $
$0
Form type
4
Date filed
3/5/2025, 04:11 PM
Next filing
Mar 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +31.8K +16.52% $0.00 224K Mar 1, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to buy) Award $0 +112K $0.00 112K Mar 1, 2025 Common Stock 112K $1.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on March 1, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.